Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept and Certolizumab Pegol, in 63,930 Patient Samples

Biologic therapeutic drug monitoring (TDM) of TNF-inhibitor drug and anti-drug antibody provides patient-specific pharmacokinetic and immunogenic assessment and informs the very different medication decisions of whether to increase the same biologic or to switch drug, in- or out-of class.